Association of baseline severity of lower urinary tract symptoms with the success conservative therapy for urinary incontinence in women

  • Aneta OblozaEmail author
  • Roderick Teo
  • Emily Marriott
  • Gillian Parker
  • Douglas Tincello
Original Article


Introduction and hypothesis

To identify the association between the symptom severity and outcome of conservative management for OAB, SUI and MUI. Conservative treatments are recommended for overactive bladder (OAB), stress urinary incontinence (SUI) and mixed incontinence (MUI). It is unclear whether disease severity affects treatment outcome.


Patients receiving conservative management were reviewed. Disease-specific questionnaires (OAB-q SF, ICIQ-UI SF) and bladder diaries recorded baseline symptoms. Success was defined by Patient Global Impression of Improvement questionnaire (PGI-I) response of “very much better” or “much better”. Non-parametric statistical tests and logistic regression were used.


In 50 OAB patients success was associated with lower symptom severity [30 (0–80) vs. 80 (23–100), p = 0.0001], fewer urgency episodes [4 (0–12) vs. 6 (0–11), p = 0.032] and lower ICIQ-UI SF [5.5 (0–20) vs. 15 (0–21), p = 0.002], but higher QoL [67 (20–101) vs. 24 (6–58), p = 0.0001]. In 50 MUI patients, variables were fewer urgency episodes [3 (0–10) vs. 6 (0–16), p = 0.004] and lower ICIQ-UI [11 (1–18) vs. 15 (5–21), p = 0.03]. In 40 SUI patients, variables were fewer incontinence episodes [1 (0–4) vs. 2 (0–5), p = 0.05] and lower ICIQ-UI [11 (6–16) vs. 13.5 (11–19), p = 0.003]. Multiple regression confirmed OAB-q QoL [odds ratio (OR) 1.10 (95% confidence intervals 1.04, 1.1)] for OAB, urgency episodes [OR 0.74 (0.56, 0.98)] and ICIQ-UI [OR 0.83 (0.71, 0.98] for MUI and ICIQ-UI [OR 0.57 (0.40, 0.83)] for SUI.


Milder baseline disease severity was associated with successful outcome. There is potential for triage at initial assessment to second-line interventions for women unlikely to achieve success.


Conservative therapy OAB Symptom severity Urinary incontinence 


Compliance with ethical standards

This work took place at the Leicester General Hospital NHS Trust, UK.

No ethical approval was required for this work.

Conflicts of interest



  1. 1.
    Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95.CrossRefPubMedGoogle Scholar
  3. 3.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.CrossRefPubMedGoogle Scholar
  4. 4.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.PubMedGoogle Scholar
  5. 5.
    Practice Bulletin no. 155: Urinary incontinence in women. Obstetrics and Gynecology. 2015;126(5):e66–e81.Google Scholar
  6. 6.
    Goldman HB, Wyndaele JJ, Kaplan SA, Wang JT. Defining response and non-response to treatment in patients with overactive bladder: a systematic review. Curr Med Res Opin. 2014;30(3):509–26.CrossRefPubMedGoogle Scholar
  7. 7.
    Chapple CR, Kelleher CJ, Evans CJ, Kopp Z, Siddiqui E, Johnson N, et al. A narrative review of patient reported outcomes in overactive bladder: what is the way of the future? Eur Urol. 2016;70:799–805.CrossRefPubMedGoogle Scholar
  8. 8.
    Burgio KL, Goode PS, Locher JL, Richter HE, Roth DL, Wright KC, et al. Predictors of outcome in the behavioural treatment of urinary incontinence in women. Obstet Gynecol. 2003;102:940–7.PubMedGoogle Scholar
  9. 9.
    Cammu H, van Nylen M. Pelvic floor exercises: 5 years later. Urology. 1995;45:113–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Burgio KL, Whitehead WE, Engel BT. Urinary incontinence in elderly: bladder sphincter biofeedback and toileting skills training. Ann Intern Med. 1985;104:507–15.CrossRefGoogle Scholar
  11. 11.
    Owen RK, Abrams KR, Mayne C, Slack M, Tincello DG. Patient factors associated with Onabotulinum toxin A treatment outcome in women with detrusor overactivity. Neurourol Urodyn. 2017;36:426–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Schaffer J, Nager CW, Xiang F, Borello-France D, Bradley CS, Wu JM, et al. Predictors of success and satisfaction of non-surgical therapy for stress urinary incontinence. Obstet Gynecol. 2013;120(1):91–7.CrossRefGoogle Scholar
  13. 13.
    Ostaszkiewicz J, Chestney T, Roe B. Habit retraining for the management of urinary incontinence in adults. Cochrane Database Syst Rev. 2004;(2):CD002801.Google Scholar
  14. 14.
    Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev. 2004;(1):CD001308.Google Scholar
  15. 15.
    Dumoulin C, Hay-Smith EJC, Mac Habée-Séguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2014;(5):CD005654.Google Scholar
  16. 16.
    Jackson S, Donovan S, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol lower urinary tract symptoms questionnaire: development and psychometric testing. BJU. 1996;77:805–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Laycock J. Clinical evaluation of the pelvic floor. In: Schussler B, Laycock J, Norton P, Stanton SL, editors. Pelvic floor re-education. London: Springer-Verlag; 1994. p. 42–8.Google Scholar
  19. 19.
    Srikrishna S, Robinson D, Cardozo L. Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. Int Urogynecol J. 2010;21(5):523–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Hendriks EJ, Kessels AG, de Vet HC, Bernards AT, de Bie RA. Prognostic indicators of poor short-term outcome of physiotherapy intervention in women with stress urinary incontinence. Neurourol Urodyn. 2010;29:336–43.PubMedGoogle Scholar
  21. 21.
    Ghei M, Malone-Lee J. Using the circumstances of symptom experience to assess the severity of urgency in the OAB. J Urol. 2005;171:972–6.CrossRefGoogle Scholar
  22. 22.
    Chapple C, Khullar V, Nitti VW, Frankel J, Herschorn S, Kaper M, et al. Efficacy of the beta3-adrenoreceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post-hoc analysis of pooled data from three randomised phase 3 trials. Eur Urol. 2015;67:11–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Hsiao SM, Lin HH, Kuo HC. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Neurourol Urodyn. 2014;33(3):331–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Serati M, Braga A, Siesto G, et al. Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder. Urology. 2013;82:1044–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Labrie J, Lagro-Jassen ALM, Fischer K, et al. Predicting who will undergo surgery after physiotherapy for female stress urinary incontinence. Int Urogynecol J. 2015;26:329–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Hendricks EJM, Kessels AGH, de Vet HCW, et al. Prognostic indicators of poor short-term outcome of physiotherapy intervention in women with stress urinary incontinence. Neurourol Urodyn. 2008;27(5):379–87.CrossRefGoogle Scholar
  27. 27.
    Schaffer J, Nager CW, Xiang F, et al. Predictors of success and satisfaction of non-surgical therapy for stress urinary incontinence. Obstet Gynecol. 2012;120(1):91–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Klovning A, Avery K, Sandvik H, Hunskaar S. Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn. 2009;28(5):411–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Bo K, Larsen S. Pelvic floor muscle exercise for the treatment of female stress urinary incontinence: classification and characterisation of responders. Neurourol Urodyn. 1992;11:497–507.CrossRefGoogle Scholar
  30. 30.
    Neumann PB, Grimmer KA, Deenadayalan Y. Pelvic floor muscle training and adjunctive therapies for the treatment of stress urinary incontinence in women: a systematic review. BMC Womens Health. 2006;6:11.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Knight S, Laycock J, Naylor D. Evaluation of neuromuscular electrical stimulation in the treatment of genuine stress incontinence. Physiotherapy. 1998;84(2):61–71.CrossRefGoogle Scholar
  32. 32.
    Turkan A, Inci Y, Fazli D. The short-term effects of physical therapy in different intensities of urodynamic stress incontinence. Gynecol Obstet Investig. 2005;59:43–8.CrossRefGoogle Scholar
  33. 33.
    Dumoulin C, Desmeule F, Hagen S, Masse BR, Mayrand M-H, Morin M, et al. Development and validation of a clinical prediction rule to guide and improve the treatment of female stress urinary incontinence. Accessed 13 Apr 2018.

Copyright information

© The International Urogynecological Association 2018

Authors and Affiliations

  1. 1.Urogynaecology DepartmentUniversity Hospitals of Leicester, NHS TrustLeicesterUK
  2. 2.Urogynaecology DepartmentLeicester General HospitalLeicesterUK
  3. 3.University of LeicesterLeicesterUK

Personalised recommendations